Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors

被引:23
作者
Juhlin, T
Björkman, S
Gunnarsson, B
Fyge, A
Roth, B
Höglund, P
机构
[1] Univ Lund Hosp, Dept Clin Pharmacol, S-22185 Lund, Sweden
[2] Malmo Univ Hosp, Dept Cardiol, Malmo, Sweden
[3] Malmo Univ Hosp, Hosp Pharm, Malmo, Sweden
关键词
ACE-inhibitors; NSAIDs; heart failure; renal function; coronary artery disease; aspirin;
D O I
10.1016/j.ejheart.2004.02.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-steroidal anti-inflammatory drugs (NSAID) or high doses of aspirin (acetylsalicylic acid) can exert detrimental effects on renal function and counteract the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in patients with congestive heart failure. Aims: The objective of our study was to evaluate the renal effects of low dose aspirin and the NSAID diclofenac in patients with congestive heart failure treated with ACE-inhibitors. Methods: Ten patients on their individually titrated dose of ACE-inhibitors and low dose aspirin (less than or equal to 125 mg daily) with stable congestive heart failure from coronary artery disease, entered an open investigation while on low dose aspirin, which was then discontinued. After one week wash-out they received an oral dose of 50 mg diclofenac potassium or placebo in a double-blind cross-over fashion with a one week wash-out period between treatments. Results: Diclofenac caused significant (P<0.05) decreases in GFR, urine flow, osmolality clearance, and excretion rates of sodium and potassium compared to placebo and aspirin. At t(max) for diclofenac or corresponding time for placebo diclofenac caused 40 (11-59)% (geometric mean and 95% confidence limits) reduction in GFR compared to placebo and 36 (5.4-56)% reduction to low-dose aspirin. No significant changes between low dose aspirin and placebo were found. Conclusion: Acute administration of diclofenac, but not long term low dose aspirin, has profound impact on renal function in patients with heart failure treated with ACE-inhibitors and may cause worsened heart failure. (C) 2004 European Society of Cardiology. Published by Elsevier B.V All rights reserved.
引用
收藏
页码:909 / 916
页数:8
相关论文
共 38 条
  • [1] Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial
    Al-Khadra, AS
    Salem, DN
    Rand, WM
    Udelson, JE
    Smith, JJ
    Konstam, MA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 419 - 425
  • [2] EVIDENCE FOR AN INVIVO ANTAGONISM BETWEEN VASOPRESSIN AND PROSTAGLANDIN IN MAMMALIAN KIDNEY
    ANDERSON, RJ
    BERL, T
    MCDONALD, KM
    SCHRIER, RW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1975, 56 (02) : 420 - 426
  • [3] ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither
    Baigent, C
    Collins, R
    Appleby, P
    Parish, S
    Sleight, P
    Peto, R
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1998, 316 (7141): : 1337 - 1343
  • [4] BALL SG, 1993, LANCET, V342, P821
  • [5] BAUR LHB, 1995, BRIT HEART J, V73, P227
  • [6] Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease
    Cleland, JGF
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2002, 44 (04) : 275 - 292
  • [7] No reduction in cardiovascular risk with NSAIDs - including aspirin?
    Cleland, JGF
    [J]. LANCET, 2002, 359 (9301) : 92 - 93
  • [8] CLELAND JGF, 1995, BRIT HEART J, V74, P215
  • [9] Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?
    Cleland, JGF
    John, J
    Houghton, T
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2001, 10 (05) : 625 - 631
  • [10] Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure
    Davie, AP
    Love, MP
    McMurray, JJV
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (05) : 530 - 537